Search

Displaying results 2631 - 2640 of 8469 in total
  1. Drug

    Malacidin A

    go.drugbank.com/drugs/DB14051
    Experimental

    Malacidin A, along with DB14052, is a member of a class of chemicals made by bacteria found in soil that can kill Gram-positive bacteria . Malacidins are 10-member macrocycle lipopeptides discovered via gene sequencing and bioinformatic ...

  2. Drug

    Zinc chloride

    go.drugbank.com/drugs/DB14533
    Approved

    [L14189] Zinc chloride was granted FDA approval before 26 June 1986.[L14189]

  3. Drug

    Madecassoside

    go.drugbank.com/drugs/DB15532
    Investigational

    Mixtures: Dr.Different CICA Metal Calming Pad
  4. Drug

    Bambusa vulgaris top

    go.drugbank.com/drugs/DB14321
    Investigational

    Bambusa vulgaris top is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.

    Mixtures: Slumber Soothe Detox Foot Pads
  5. Drug

    Temoporfin

    go.drugbank.com/drugs/DB11630
    Approved

    It was first authorized for market by the European Medicines Agency in October 2001. It is currently available under the brand name Foscan.

  6. Drug

    Laromustine

    go.drugbank.com/drugs/DB05817
    Investigational

    VNP40101M is a novel alkylating agent that has been used in trials studying the treatment of Leukemia, Lymphoma, Lung Cancer, Small Intestine Cancer, and Myelodysplastic Syndromes, among others.

  7. Drug

    Platycodon grandiflorus root

    go.drugbank.com/drugs/DB14347
    Investigational

    Platycodon grandiflorus root is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.

    Mixtures: Slumber Soothe Detox Foot Pads
  8. Drug

    Nemolizumab

    go.drugbank.com/drugs/DB15252
    ApprovedInvestigational

    [A264274] It was later approved by the FDA on August 13, 2024, for the treatment of prurigo nodularis.[L51169]

  9. Drug

    CNS-5161

    go.drugbank.com/drugs/DB05824
    Experimental

    CNS 5161 is a blocker of the NMDA ion channel and has completed Phase IIa proof of concept clinical trials as a novel compound for the treatment of neuropathic pain.

  10. Drug

    T487

    go.drugbank.com/drugs/DB05474
    Experimental

    The formulation is administered orally and has anti-inflammatory effects in conditions such as rheumatoid arthritis, inflammatory bowel disease and psoriasis.